List view / Grid view
4 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival...
18 July 2014 | By Amgen
Amgen announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease...
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
10 June 2014 | By Amgen
Amgen announced the appointment of David W. Meline as executive vice president and chief financial officer, effective July 21, 2014...
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
28 May 2014 | By Amgen
New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform...
19 May 2014 | By AbbVie
AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
In this Raman Spectroscopy In-Depth Focus 2014: Raman spectroscopy in the study of pharmaceuticals: the problems and solutions to sub-sampling and data analysis; Conformational state analysis of proteins by Raman spectroscopy: univariate and multivariate methods; Raman Roundtable...
7 April 2014 | By Amgen
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec...
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
12 March 2014 | By Amgen
Amgen announced the appointment of David Piacquad to the new position of senior vice president, Business Development...
11 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
5 February 2014 | By Amgen
Amgen and Merck announced that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec...
